Fortin, David

Professeur, Faculté de médecine et des sciences de la santé
FMSS Département de chirurgie

Coordonnées

Courriel


819-821-8000, poste 75034

Diplômes

(1999) Doctorat (Diplôme d'études spécialisées en médecine - professionnels de la santé).

(1998) Doctorat (Diplôme d'études spécialisées en médecine - professionnels de la santé). University of Western Ontario.

(1997) Diplôme (Diplôme d'études spécialisées en médecine). Université de Sherbrooke.

(1991) Doctorat (Doctor of Medicine - M.D.). Université de Sherbrooke.

Titres de compétence

Directeur de l'équipe de neuro-oncologie de niveau 4 du RUIS Sherbrooke. Centre Hospitalier Univ. de Sherbrooke.

Directeur du programme clientèle d'oncologie du CHUS. Centre Hospitalier Univ. de Sherbrooke.

fellow du collège royal.

neurochirurgien.

Présentation

Sujets de recherche

Facteurs de croissance, Interaction hôte-tumeur, Neurogénèse et gliogénèse, Thérapie génique du cancer, Tumeurs cérébrales.

Disciplines de recherche

Neurosciences, Oncologie.

Mots-clés

BBB manipulation, Blood-brain barrier (BBB), brain tumours, chemotherapy, CNS delivery, glioma implantation model, Glioma models, immunohistochemistry, liposomes, Neuro-oncology.

Intérêts de recherche

Barrière hémato-encéphalique et livraison de molécules au système nerveux central. Chimiorésistance reliée à l'expression des pompes à efflux au niveau de la BHE et des cellules gliales Imagerie fonctionnelle et anatomique cérébrale

Recherche clinique

Oui

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2010) Prix César Galéano, professeur le plus apprécié à la faculté de médecine par les étudiants du premier cycle. Université de Sherbrooke. (Prix / Récompense).
  • (2003) personnalité de l'année. (Distinction).
  • (2003) Mérite Estrien 2003. (Distinction).
  • Prix César-Galéano. (Distinction).
  • Prix du rayonnement, gala annuel de la recherche. (Distinction).

Publications

Articles de revue

  • Chantal M W Tax · Maxime Chamberland · Marijn van Stralen · Max A Viergever · Kevin Whittingstall · David Fortin · Maxime Descoteaux · Alexander Leemans. (2015). Seeing More by Showing Less: Orientation-Dependent Transparency Rendering for Fiber Tractography Visualization. PLOS ONE 10(10):E0139434, 10(10), E0139434.
  • Maxime Chamberland · Michaël Bernier · David Fortin · Kevin Whittingstall · Maxime Descoteaux. (2015). 3D interactive tractography-informed resting-state fMRI connectivity. Frontiers in neuroscience, 9(275), 1-15.
  • Annie Drapeau, David Fortin. (2015). Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous. Curr Cancer Drug Targets, 15(1), (Article accepté).
  • (2015). Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta. Invest New Drugs, 2015, 1-12, 1-12. (Article accepté).
  • Mingan Shi, Leon Sanche, Benoit Paquette. (2015). Convection-enhancement delivery of platinum-based drugs and Lipoplatin(TM) to optimize the concomitant effect with radiotherapy in F98 glioma rat model. Invest New Drugs, 33(3), 555-563. (Article publié).
  • Guillaume Desmarais · Gabriel Charest · David Fortin · Rachel Bujold · David Mathieu · Benoit Paquette. (2015). Cyclooxygenase-2 inhibitor prevents radiation-enhanced infiltration of F98 glioma cells in brain of Fischer rat. international journal of radiation biology, 91(8), 1-38. (Article publié).
  • Blanchette M, Pellerin M, Tremblay L, Lepage M, Fortin D. (2014). Real time monitoring of Gd-DTPA during osmotic blood brain barrier disruption using MRI in normal Wistar rats. Neurosurgery, 65(2), 344-51. (Article publié).
  • Whittingstall K , Bernier M , Houde JC , Fortin D , Descoteaux M. (2014). Structural network underlying visuospatial imagery in humans. Cortex; a journal devoted to the study of the nervous system and behavior, 56, 85-98.
  • Fortin D, Morin PA, Belzile F, Mathieu D, Paré FM. (2014). Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme. Journal of Neurooncology, (Article publié).
  • Blanchette M, Tremblay L, Lepage M, Fortin D. (2014). Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption. Journal of Cerebral Blood Flow & Metabolism, 34(5), 820-826. (Article publié).
  • Chamberland M, Whittingstall K, Fortin D, Mathieu D, Descoteaux M. (2014). Real-time multi-peak tractography for instantaneous connectivity display. Frontiers in Neuroinformatics, 8(59),
  • Chamberland M, Whittingstall K, Fortin D, Mathieu D, Descoteaux M. (2014). Real-time multi-peak tractography for instantaneous connectivity display. Frontiers in Neuroinformatics, 30(8), 59. (Article publié).
  • Gadji M , Crous-Tsanaclis AM , Mathieu D , Mai S , Fortin D , Drouin R. (2014). A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component. Neuropathology : official journal of the Japanese Society of Neuropathology,
  • Carolyne Lowry, Marie-Belle Poirier, David Fortin, J. Richard Wagner. (2014). Alterations in Epigenetic Markers Related to 5-Hydroxymethylcytosine in Brain Cancer. free radical biology and medicine, supplement 1(76), s134-s135. (Article publié).
  • Roy LO, Poirier MB, Fortin D. (2014). Transforming Growth Factor-beta (TGF-β) and its implication in the malignancy of gliomas. Targeted Oncology, (Révisions requises).
  • Roy LO, Poirier MB, Fortin D. (2014). Transforming growth factor-beta and its implication in the malignancy of gliomas. Traget Oncology, (Article accepté).
  • Charest G , Sanche L , Fortin D , Mathieu D , Paquette B. (2013). Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain. Journal of neuro-oncology, 115(3),
  • Daigle K , Fortin D , Mathieu D , Saint-Pierre AB , Paré FM , de la Sablonnière A , Goffaux P. (2013). Effects of surgical resection on the evolution of quality of life in newly diagnosed patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion, 29(10),
  • Côté J , Savard M , Neugebauer W , Fortin D , Lepage M , Gobeil F. (2013). Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors. Cancer biology & therapy, 14(9),
  • Fortin D, Aubin-Lemay C, Boré A, Girard G, Houde JC, Whittingstall K, Descoteaux K. (2012). Major fiber bundles and function systems of the human brain highlighted by tractography: a neurosurgical view. CJNS, (Article accepté).
  • Fortin D , Aubin-Lemay C , Boré A , Girard G , Houde JC , Whittingstall K , Descoteaux M. (2012). Tractography in the study of the human brain: a neurosurgical perspective. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 39(6),
  • Dea N , Fournier-Gosselin MP , Mathieu D , Goffaux P , Fortin D. (2012). Does extent of resection impact survival in patients bearing glioblastoma?. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 39(5),
  • Charest G , Sanche L , Fortin D , Mathieu D , Paquette B. (2012). Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy. International journal of radiation oncology, biology, physics, 84(1),
  • Desmarais G , Fortin D , Bujold R , Wagner R , Mathieu D , Paquette B. (2012). Infiltration of glioma cells in brain parenchyma stimulated by radiation in the F98/Fischer rat model. International journal of radiation biology, 88(8),
  • Blanchette M , Michaud K , Fortin D. (2012). A new method of quantitatively assessing the opening of the blood-brain barrier in murine animal models. Journal of neuroscience methods, 207(2),
  • Fortin D. (2012). The blood-brain barrier: its influence in the treatment of brain tumors metastases. Current cancer drug targets, 12(3),
  • Côté J , Bovenzi V , Savard M , Dubuc C , Fortier A , Neugebauer W , Tremblay L , Müller-Esterl W , Tsanaclis AM , Lepage M , Fortin D , Gobeil F. (2012). Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. PloS one, 7(5),
  • Montagne M , Beaudoin N , Fortin D , Lavoie CL , Klinck R , Lavigne P. (2012). The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. PloS one, 7(2),
  • Veilleux N , Goffaux P , Boudrias M , Mathieu D , Daigle K , Fortin D. (2011). Quality of life in neurooncology--age matters. Journal of neurosurgery, 113(2),
  • Blanchette M , Fortin D. (2011). Blood-brain barrier disruption in the treatment of brain tumors. Methods in molecular biology (Clifton, N.J.), 686,
  • Dea N , Borduas M , Kenny B , Fortin D , Mathieu D. (2010). Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations. Journal of neurosurgery, 113 Suppl,
  • Goffaux P , Fortin D. (2010). Brain tumor headaches: from bedside to bench. Neurosurgery, 67(2),
  • Charest G , Paquette B , Fortin D , Mathieu D , Sanche L. (2010). Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation. Journal of neuro-oncology, 97(2),
  • Côté J , Savard M , Bovenzi V , Dubuc C , Tremblay L , Tsanaclis AM , Fortin D , Lepage M , Gobeil F. (2010). Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides, 44(2),
  • Gadji M , Crous AM , Fortin D , Krcek J , Torchia M , Mai S , Drouin R , Klonisch T. (2009). EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. European journal of pharmacology, 625(1-3),
  • Gadji M , Fortin D , Tsanaclis AM , Drouin R. (2009). Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?. Cancer genetics and cytogenetics, 194(1),
  • Charest G , Mathieu D , Lepage M , Fortin D , Paquette B , Sanche L. (2009). Polymer gel in rat skull to assess the accuracy of a new rat stereotactic device for use with the Gamma Knife. Acta neurochirurgica, 151(6),
  • Goffaux P , Boudrias M , Mathieu D , Charpentier C , Veilleux N , Fortin D. (2009). Development of a concise QOL questionnaire for brain tumor patients. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 36(3),
  • Mathieu D , Kondziolka D , Flickinger JC , Fortin D , Kenny B , Michaud K , Mongia S , Niranjan A , Lunsford LD. (2008). Tumor bed radiosurgery after resection of cerebral metastases. Neurosurgery, 62(4),
  • Jahnke K , Kraemer DF , Knight KR , Fortin D , Bell S , Doolittle ND , Muldoon LL , Neuwelt EA. (2008). Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer, 112(3),
  • Bellavance MA , Blanchette M , Fortin D. (2008). Recent advances in blood-brain barrier disruption as a CNS delivery strategy. The AAPS journal, 10(1),
  • Mathieu D , Fortin D. (2007). Chemotherapy and delivery in the treatment of primary brain tumors. Current clinical pharmacology, 2(3),
  • Mathieu D , Lecomte R , Tsanaclis AM , Larouche A , Fortin D. (2007). Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 34(3),
  • Fortin D , Gendron C , Boudrias M , Garant MP. (2007). Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer, 109(4),
  • Hall WA , Doolittle ND , Daman M , Bruns PK , Muldoon L , Fortin D , Neuwelt EA. (2006). Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. Journal of neuro-oncology, 77(3),
  • Mathieu D , Fortin D. (2006). The role of chemotherapy in the treatment of malignant astrocytomas. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 33(2),
  • Blanchard J , Mathieu D , Patenaude Y , Fortin D. (2006). MR-pathological comparison in F98-Fischer glioma model using a human gantry. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 33(1),
  • Mathieu D , Fortin D. (2005). Intracranial invasion of a basal cell carcinoma of the scalp. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 32(4),
  • Fortin D , Desjardins A , Benko A , Niyonsega T , Boudrias M. (2005). Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer, 103(12),
  • Larouche A , Roy M , Kadhim H , Tsanaclis AM , Fortin D , Sébire G. (2005). Neuronal injuries induced by perinatal hypoxic-ischemic insults are potentiated by prenatal exposure to lipopolysaccharide: animal model for perinatally acquired encephalopathy. Developmental neuroscience, 27(2-4),
  • Fortin D , Adams R , Gallez A. (2004). A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 31(2),
  • Fortin D , Salamé JA , Desjardins A , Benko A. (2004). Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor. AJNR. American journal of neuroradiology, 25(5),
  • Fortin D. (2004). [The blood-brain barrier should not be underestimated in neuro-oncology]. Revue neurologique, 160(5 Pt 1),
  • Fortin D. (2003). Altering the properties of the blood-brain barrier: disruption and permeabilization. Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques, 61,
  • Roberts JM , Diaz AR , Fortin DT , Friedle JM , Piper SD. (2002). Influence of the hofmeister series on the retention of amines in reversed-phase liquid chromatography. Analytical chemistry, 74(19),
  • Kraemer DF , Fortin D , Neuwelt EA. (2002). Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. Current neurology and neuroscience reports, 2(3),
  • Fisher BJ , Naumova E , Leighton CC , Naumov GN , Kerklviet N , Fortin D , Macdonald DR , Cairncross JG , Bauman GS , Stitt L. (2002). Ki-67: a prognostic factor for low-grade glioma?. International journal of radiation oncology, biology, physics, 52(4),

Chapitres de livre

  • (2015). Contextual diffusion image post-processing aids clinical applications. Visualization and Processing of Higher Order Descriptors for Multi-Valued Data (1, 1, 353-379). Springer. (Article publié).
  • Fortin D, Goffaux P. (2012). Headaches in Patients with Brain Tumors. Tumors of the central nervous system (4, 325-334). E Hayat. (Article publié).
  • Daigle K, Goffaux P, Fortin D. (2012). Patients with Brain Cancer: Health Related Quality of Life. Tumors of the central nervous system (4, 341-348). E Hayat. (Article publié).
  • Fortin D. (2011). Fischer/F98 glioma model: Methodology. Methods of Cancer Diagnosis, Therapy and Prognosis (2, 349-359). Springer. (Article publié).

Articles de journaux

  • Mathieu D, Lamarche J, Fortin D, Jacques B. The importance of a syngeneic glioma implantation model: comparison of the F98 cell line in Fischer and Long-Evans rats. The Journal of Applied Research. 17-25.

Propriétés intellectuelles

Brevets

  • (2012). BRADYKININ B1 RECEPTOR PEPTIDE AGONISTS. (Terminé).

Autres contributions

Cours enseignés

  • neuro-anatomie, une introduction. Université de Sherbrooke. Canada.

Présentations

  • (2015). Impact de la localisation cérébrale de glioblastomes sur la qualité de vie. Journée scientifique de chirurgie, université de sherbrooke. Sherbrooke.
  • (2015). Glioblastomas Located in the Right Hemisphere are Associated with Worse Quality of Life. Congress of neurosurgery. nouvelle-orléans.
  • (2015). Interactively computing and visualizing functional and structural brain connectivity in real-time. ISMRM. toronto.
  • (2015). Tractography-driven resting-state fMRI for investigating inter-subject variability. OHBM. honolulu.
  • (2014). Acheminement différentiel d’agents de poids moléculaires différents au-delà de la barrière hémato-encéphalique dans le traitement de gliomes malins. SNCLF. Paris.
  • (2014). Tractographie « multi-peak » en temps réel dans la planification de chirurgie d’exérèse de tumeurs gliales : un outil permettant un ajustement fin de la fraction anisotropique (FA). SNCLF. Paris.
  • (2014). TBI Prognosis Calculator: une application mobile estimant la mortalité et la morbidité secondaire aux traumatismes crâniens. ANCQ. montréal.
  • (2014). TBI Prognosis: A mobile application to estimate mortality and morbidity following traumatic brain injury. Congress of neurological surgeons 2014. Boston.
  • (2014). The future directions in surgical care of high grade gliomas. 16th biennial Canadian neuro-oncology meeting.
  • (2014). Simultaneously probing functional and structural brain connectivity in real-time Fibernavigator: An interactive tool for brain visualization. Neurotechnix. rome.
  • (2013). L'ouverture osmotique de la barrière hémato-encéphalique, une stratégie de livraison au système nerveux central à toute épreuve?. 5ième journée scientifique du Centre des Neurosciences de Sherbrooke. Sherbrooke.
  • (2013). Le processus d'ouverture osmotique de la barrière hémato-encéphalique permet-il l'acheminement de tout composé au système nerveux central?. Journée scientifique du Centre d'imagerie moléculaire de Sherbrooke et de l'Axe Imagerie Médicale du CRCÉLB. Sherbrooke.
  • (2013). La chloroquine comme inhibiteur de la maturation du Transforming Growth Factor-beta (TGF-b) et du caractère invasif des glioblastomes (GBM). Société de Neurochirurgie de Langue Française (SNCLF) et de l’Association de Neurochirurgie du Québec (ANCQ). Québec.
  • (2013). L’interférence par ARN contre la voie du Transforming Growth Factor-beta (TGF‑b) : un traitement contre le caractère malin dans les glioblastomes (GBM). Société de Neurochirurgie de Langue Française (SNCLF) et de l’Association de Neurochirurgie du Québec (ANCQ). Québec.
  • (2013). Effet d'un traitement de témozolomide par infusion intra-artérielle avec ou sans ouverture osmotique de la barrière hémato-encéphalique. Société de Neurochirurgie de Langue Française (SNCLF) et de l’Association de Neurochirurgie du Québec (ANCQ). Québec.
  • (2013). Les barrières hémato-encéphalique et hémato-tumorale, évidence d’une limitation en neuro-oncologie. Société de Neurochirurgie de Langue Française (SNCLF) et de l’Association de Neurochirurgie du Québec (ANCQ). Québec.
  • (2013). CHARACTERIZATION OF INDIVIDUAL TELOMERES LENGTHENING IN GLIOBLASTOMA MULTIFORME. 1st Canadian Symposium on Telomeres and Genome Integrity. London.
  • (2012). Étude de l’expression de gènes impliqués dans l’invasion et la résistance aux agents néoplasiques dans des spécimens de gliobalstomes multiformes. ANCQ 2012. Mont-Orford.
  • (2012). Évaluation des capacités radiosensibilisantes de composés platinés dans le traitement des glioblastomes. ANCQ 2012. Mont-Orford.
  • (2012). Évaluations neurocognitives de patients atteints de tumeur cérébrale primaire. ANCQ 2012. Mont-Orford.
  • (2012). Osmotic blood-brain barrier disruption as delivery strategy to bypass the blood-tumor barrier. 10th Meeting of the European Association of Neuro-Oncology. Marseille.
  • (2012). Pharmacological evaluation of novel fluorescently-labeled analogs of Icatibant. 22nd American peptide symposium. San Diego.
  • (2012). Induction of selective blood-brain-barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. Kinin 2012.
  • (2012). Imagerie cérébrale, neuro-cognition et qualité de vie: des enjeux majeurs en neuro-oncologie. Imagerie cérébrale. La Malbaie.
  • (2012). La recherche clinique en oncologie: du laboratoire au patient, et vice‐versa!. Mieux comprendre le cancer en 2012.
  • (2012). DCE-MRI and ICP-MS evaluation of biodistribution of contrast agents and chemotherapeutic agents to gliomas with a new pharmacological approach in F98 glioma cells implanted Fischer rats. ISMRM. Melbourne.
  • (2011). La barrière hémato-encéphalique, l'évidence d'une limitation en neuro-oncologie. 3e Journée scientifique du Centre des neurosciences de Sherbrooke. Sherbrooke.
  • (2011). Évaluations neuropsychologiques de patients atteints de tumeur cérébrale primaire : implications et perspectives. Journée scientifique du Centre des Neurosciences de Sherbrooke. Sherbrooke.
  • (2011). La barrière hémato-encéphalique, l'évidence d'une limitation en neuro-oncologie. Journée scientifique du département de chirurgie du CHUS. Sherbrooke.
  • (2011). How new imaging tools improve glioma surgery. Halifax Brain Tumour Information Day Conference. Halifax.
  • (2011). Influence de la masse tumorale et de l'étendue de l'exérèse chirurgicale sur la qualité de vie en neuro-oncologie. Congrès de la Recherche Clinique du Québec. Sainte-Adèle.
  • (2011). Évaluation comparative de différents traitements (5 composés platinés en 3 routes d'administration) combinés ou non avec la radiation ionisante pour améliorer les traitements de glioblastome. 10e congrès de la société internationale de radiobiologie de la langue française. Anglet.
  • (2011). DCE-MRI for chemotherapy treatment planning in neuro-oncology. World molecular imaging congress. San Diego.
  • (2011). Glioblastoma treatment: comparative studies of three routes of administration, platinum formulations and combination or not with radiation: in vivo experiments. Brain 2011 - The XXVth international symposium on cerebral blood flow metabolism and function and the Xth internation conference on quantification of brain function with PET.
  • (2011). Potential use of synthetic kinin B1 receptor agonists as permeability enhancers for improving drug delivery to malignant brain tumours. CSPT annual conference. Montréal.
  • (2010). For a better treatment of brain tumour by optimizing the concomitance treatment of radiotherapy with liposomal and non liposomal platinum drugs. International Workshop on Radiosensitization: From Fundamental Processes Involved in Radiosensitization to Biological Applications.
  • (2010). Comparative evaluation of liposomal and nonliposomal platinum compounds combined or not with concomitant focal radiation to improve treatment of glioblastoma bearing rat. 15th Annuel Scientific Meeting of the Society for Neuro-Oncology. Montréal.
  • (2010). Comparative evaluation of liposomal and non-liposomal platinum drugs combined or not with radiation to improve treatment of glioblastoma implanted in rat brain. Rencontre annuelle 2010 IROC-CORI (Initiative de recherche en oncologie clinique). Sherbrooke.
  • (2010). Comparative evaluation of liposomal and nonliposomal platinum drugs combined or not with concomitant radiation to improve treatment of glioblastoma implanted in rat brain. 56th Annual Meeting of the Radiation Research Society. Maui.
  • (2010). Characterisation of antineoplastic agents delivery to the CNs enhanced by osmotic BBBD. Canadian Neuro-Oncology Meeting. niagara-on-the-lake.
  • (2010). DCE-MRI evaluation of inducible kinin B1 receptor-mediated selective blood-brain barrier permeabilisation in F98 glioma-bearing Fischer rats with a high molecular weight contrast agent. Bourse ACI des IRSC. Niagara-on-the-lake.
  • (2010). Glioblastoma treatment: Bypassing the toxicity of platinum compound via liposomal formulation and increasing treatment efficiency with concomitant focal radiotherapy. In vivo experiments. 14th Biennial Canadian Neuro-Oncology Meeting. Niagara-on-the-lake.
  • (2010). Glioblastoma treatment: Cationic liposomes as a potent novel treatment for primary brain tumors. 14th Biennial Canadian Neuro Oncology Meeting. Niagara-on-the-lake.
  • (2010). Glioblastoma treatment: Predictive significance of T1-weighted and FLAIR images on self-assessed QOL in neuro-oncology: a preliminary study In vivo Experiments. 14th Biennial Canadian Neuro Oncology Meeting. Niagara-on-the-lake.
  • (2010). Predictive significance of T1-weighted and FLAIR images on self-assessed QOL in neuro-oncology: a preliminary study. 14th Biennial Canadian Neuro-Oncology Meeting. Niagara-on-the-lake.
  • (2010). DCE-MRI evaluation of inducible kinin B1 receptor-mediated selective blood-brain barrier permeabilisation in F98 glioma-bearing Fischer rats with a high molecular weight contrast agent. ISMRM.
  • (2009). Role of radiation to stimulate the proliferation and invasiveness of F98 glioma cells implanted in rat brain. Radiation Research Society 55th Annual Meeting. Savannah, Géorgie.
  • (2009). Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model. The 5th International Symposium Peptide Receptors & Kinin. Québec.
  • (2008). Bypassing the stereotactic imaging step prior Gamma knife radiosurgery for recurrent experiments in small animals. 8th Meeting of the European Association of Neuro-Oncology.
  • (2008). Real time monitoring of kinin B1 receptor-mediated blood-brain barrier disruption in a F98 glioma rat model using MRI. 8th Congress of the European Association of Neuro-Oncology.
  • (2008). Targeted delivery to brain tumors using liposomes. 8th Congress of the European Association of Neuro-Oncology.
  • (2008). Improvement of radiation efficacy for brain cancer F98 glioma by adding concomitant platinum compounds. European Radiation Research Society. Tours.
  • (2008). Use of polymer gel for bypassing the stereotactic imaging step prior Gamma knife radio surgery in small animals. European Radiation Research Society. Tours.
  • (2008). Est-ce possible d'acheminer de grosses molécules au sein du système nerveux central?. 2nd Annual Meeting of the Canadian Association for Neuroscience. Montréal.
  • (2008). Utilisation of polymer gel dosimeter implanted in rat head for targeting experiments using the Gamma knife. 14th Leksell Gamma Knife Society Meeting. Québec.
  • (2008). Aneuploidy and chromosomal instability in gliomas (poster). Congress of the american Association for Cancer Research. San Diego.
  • (2008). Chromosomal and molecular signatures of gliomas (poster). 15th Annual Clinical Genetics Meeting of American College of Medical Genetics. Phoenix.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.